Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: Small molecule-based therapeutics for anemia

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 9, 2010, Pages 1219-1245

  Yan, Lin ^a   Colandrea, Vincent J ^a   Hale, Jeffrey J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anemia; Erythropoiesis stimulating agents; Erythropoietin; Factor inhibiting HIF; Prolyl hydroxylase domain containing protein

Indexed keywords

1 CHLORO 4 HYDROXYISOQUINOLINE GLYCINAMIDE; 4 OXO 1,4 DIHYDRO 1,10 PHENANTHROLINE 3 CARBOXYLIC ACID; ANTIANEMIC AGENT; BEVACIZUMAB; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DEFERASIROX; ERYTHROPOIETIN; FG 2216; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICERA; NAPHTHYRIDONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROLYL HYDROXYLASE DOMAIN CONTAINING PROTEIN INHIBITOR; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CARCINOGENESIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME STABILITY; GENE; GENE EXPRESSION; HUMAN; IC 50; IRON METABOLISM; NONHUMAN; OXYGEN SENSING; POLYCYTHEMIA; PROTEIN DEGRADATION; PULMONARY HYPERTENSION; REVIEW; THROMBOSIS; TREATMENT INDICATION; UPREGULATION;

ANEMIA; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PATENTS AS TOPIC; PROCOLLAGEN-PROLINE DIOXYGENASE;

EID: 77955790529     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.510836     Document Type: Review

References (224)

1. Worldwide prevalence of anaemia, 1993 2005. WHO Global Databaseon Anaemia. Available from: http://whqlibdoc.who.int/publications/2008/ 9789241596657eng.pdf.
2. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747-1750
3. Perutz MF. Structure and mechanism of hemoglobin. Br Med Bull 1976;32:195-208
4. Brown R. Plasma erythropoietin in chronic uraemia. Br Med J 1965;2:1036-1038
5. Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986;172:213-224
6. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992;72:449-489
7. Jacobs K, Shoemaker R, Rurensdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313(6005):806
8. Lin F-K, Lin P-H, Lai JK, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-7584
9. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-163
10. Eschbach JW, Abdulhadi HM, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III clinical trial. Ann Intern Med 1989;111:992-1000
11. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 2008;141:287-297
12. FibroGen, Inc. Avaialble from: anemial-market. [Accessed on 18 April 2010]
13. Wish J, Schulman K, Law A, et al. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res 2009;32:110-118
14. Semenza GL, Wang G. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-5454
15. Fraisl P, Aragones J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 2009;8:139-152
16. Semenza GL. Regulation of mammalian O2 hoeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-578
17. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993;268:21513-21518
18. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-1237
19. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82
20. Ema M, Taya S, Yokotani N, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94:4273-4278
21. Flamme I, Frohlich T, von Reutern M, et al. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1alpha and developmentally expressed in blood vessels. Mech Dev 1997;63:51-60
22. Gu Y-Z, Moran SM, Hogenesch JB, et al. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998;7:205-213
23. Hoffman EC, Reyes H, Chu FF, et al. Cloning of a factor required for activity of the Ah(dioxin) receptor. Science 1991;252:954-958
24. Li H, Ko HP, Whitlock JP. Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF 1alpha. J Biol Chem 1996;271:21262-21267
25. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 2007;117:1068-1077
26. Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008;358:162-168
27. Martini M, Teofili L, Cenci T, et al. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 2008;93:1068-1071
28. Furlow PW, Percy MJ, Sutherland S, et al. Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. J Biol Chem 2009;284:9050-9058
29. Gruber M, Hu C-J, Johnson RS, et al. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA 2007;104:2301-2306
30. Fong G-H. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med 2009;87:549-560
31. Huang LE, Arany Z, Livingston DM, et al. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996;271:32253-32259
32. Huang LE, Gu J, Schau M, et al. Regulation of hypoxia-inducible factor 1a is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987-7992
33. Semenza GL, Jiang B-H, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271:32529-32537
34. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-5514
35. Massari ME, Murre C. Helix-loop helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 2000;20:429-440
36. Moglich A, Ayers RA, Moffat K. Structure and signaling mechanism of Per-ARNT-Sim domains. Structure 2009;17:1282-1294
37. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-25741
38. Semenza GL, Nejfelt MK, Chi SM, et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 1991;88:5680-5684
39. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993;90:4304-4308
40. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors in iron metabolism. Cell Cycle 2008;7:28-32
41. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926-1932
42. Hirsila M, Koivunen P, Gunzler V. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 2003;278:30772-30780
43. Ehrismann D, Flashman E, Genn DN, et al. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem J 2007;401:227-234
44. Ivan M, Kondo K, Yang H. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-468
45. Jaakkola P, Mole DR, Tian Y-M. Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472
46. Yu F, White SB, Zhao Q, et al. HIF-1a binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001;98:9630-9635
47. Min JH, Yang H, Ivan M, et al. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 2002;296:1886-1889
48. Maxwell PH, Wiesener MS, Chang G-W, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-276
49. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-427
50. Kamura T, Sato S, Iwai K, et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-10435
51. Paltoglou S, Roberts BJ. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumor suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases. Oncogene 2007;26:604-609
52. Min J-H, Yang H, Ivan M, et al. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 2002;296:1886-1889
53. Hon W-C, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxy-proline in HIF1alpha by pVHL. Nature 2002;417:975-978
54. Berchner-Pfannschmidt U, Tug S, Trinidad B, et al. Nuclear oxygen sensing: induction of endogenous prolyl-hydroxylase 2 activity by hypoxia and nitric oxide. J Biol Chem 2008;283:31745-31753
55. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002;295:858-861
56. Wang Q, VanDusen WJ, Petroski CJ, et al. Bovine liver aspartyl beta-hydroxylase. J Biol Chem 1991;266:14004-14010
57. Dames SA, Martinez-Yamout M, De Guzman RN, et al. Structural basis for HIF1alpha/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA 2002;99:5271-5276
58. Freedman SJ, Sun Z-YJ, Poy F, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1alpha. Proc Natl Acad Sci USA 2002;99:5367-5372
59. Koivunen P, Hirsila M, Gunzler V, et al. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2004;279:9899-9904
60. Schfield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 2005;338:617-626
61. Cioffi CL, Liu XQ, Kosinski PA, et al. Differential regulation of HIF-1alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem Biophys Res Commun 2003;303:947-953
62. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 2002;296:343-349
63. Koivunen P, Tiainen P, Hyvarinen J, et al. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol Chem 2007;282:30544-30552
64. Metzen E, Berchner-Pfannschmidt U, Stengel P. Intracellular localization of human HIF-1alpha hydroxylases: implications for oxygen sensing. J Cell Sci 2003;116:1319-1326
65. Berra E, Benizri E, Ginouves, et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003;22:4082-4090
66. Berchner-Pfannschmidt U, Tug S, Trinidad B, et al. Nuclear oxygen sensing: induction of endogenous prolyl-hydroxylase 2 activity by hypoxia and nitric oxide. J Biol Chem 2008;283:31745-31753
67. Stiehl DP, Wirthner R, Koditz J, et al. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. J Biol Chem 2006;281:23482-23491
68. Clifton IJ, McDonough MA, Ehrismann D, et al. Structural studies on 2-oxoglutarate oxygenases and related double-stranded b-helix fold proteins. J Inorg Biochem 2006;100:644-669
69. Ozer A, Bruick RK. Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one? Nat Chem Biol 2007;3:144-153
70. McDonough MA, Li V, Flashman E, et al. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA 2006;103:9814-9819
71. Chowdhury R, McDonough MA, Mecinovic J, et al. Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. Structure 2009;17:981-989
72. Myllyharju J. HIF prolyl 4-hydroxylases and their potential as drug targets. Curr Pharm Des 2009;15:3878-3885
73. Bruegge K, Jelkmann W, Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 2007;14:1853-1862
74. Roy A, Volgin DV, Baby SM, et al. Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body. Neurosci Lett 2004;363:229-232
75. Linden T, Katschinski DM, Eckhardt K, et al. The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. FASEB J 2003;17:761-763
76. Hirsila M, Koivunen P, Xu L, et al. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 2005;19:1308-1310
77. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988;242:1412-1415
78. Salnikow K, Donald SP, Bruick RK, et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004;279:40337-40344
79. Kivirikko KI, Myllyla R. Posttranslational enzymes in the biosynthesis of collagen: intracellular enzymes. Methods Enzymol 1982;82:245-304
80. Kanelakis KC, Palomino HL, Li L, et al. Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases. J Biomol Screen 2009;14:627-635
81. FibroGen, Inc. HIF prolyl hydroxylase activity assay. WO2005118836; 2007
82. Li D, Hirsila M, Koivunen P, et al. Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1alpha-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases. J Biol Chem 2004;279:55051-55059
83. Dao JH, Kurzeja RJM, Morachis JM, et al. Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology. Anal Biochem 2009;384:213-223
84. Tegley CM, Viswanadhan VN, Biswas K, et al. Discovery of novel hydroxyl-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation. Bioorg Med Chem Lett 2008;18:3925-3928
85. Frohn M, Viswanadhan V, Pickrell AJ, et al. Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1alpha prolyl hydroxylase-2 inhibitors. Bioorg Med Chem Lett 2008;18:5023-5026
86. Oehme F, Jonghaus W, Narouz-Ott L, et al. A nonradioactive 96-well plate assay for the detection of hypoxia-inducible factor prolyl hydroxylase activity. Anal Biochem 2004;330:74-80
87. FibroGen, Inc. Stabilization of hypoxia inducible factor (HIF) alpha. WO2003049686; 2003
88. FibroGen, Inc. Methods of increasing endogenous EPO. WO2003053997; 2003
89. FibroGen, Inc. Treatment method for anemia. US20060276477; 2006
90. FibroGen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia. US20070292433; 2007
91. FibroGen, Inc. HIF hydroxylase inhibitors for treatment of cancer-related anemia. US20070293575; 2007
92. FibroGen, Inc. Use of HIF alpha stabilizers for enhancing erythropoiesis. WO2004108121; 2004
93. FibroGen, Inc. Cytoprotection through the use of HIF hydroxylase inhibitors. US20060251638; 2006
94. FibroGen, Inc. Fat regulation. WO2004052285; 2004
95. FibroGen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers. WO2005011696; 2005
96. FibroGen, Inc. Tissue remodeling and vascularization. WO2005034929; 2005
97. FibroGen, Inc. Treatment of diabetes. WO2004052284; 2004
98. FibroGen, Inc. Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy. WO2006099610; 2006
99. FibroGen, Inc. Compounds and methods for treatment of stroke. WO2007097929; 2007
100. FibroGen, Inc. Methods for increasing endothelial progenitor cells. WO2009075824; 2009
101. FibroGen, Inc. Methods for increasing white blood cells. WO2009075826; 2009
102. FibroGen, Inc. Compounds and methods for treatment of cancer. WO2006138511; 2006
103. FibroGen, Inc. Methods for reducing blood pressure. WO2009058403; 2009
104. FibroGen, Inc. Phenanthroline derivatives. WO9921860; 1999
105. Ivan M, Haberberger T, Gervasi DC, et al. Bichemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 2002;99:13459-13464
106. FibroGen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin. WO2004108681; 2004
107. Thevis M, Kohler M, Schlorer N, et al. Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation. J Am Soc Mass Spectrom 2008;19:151-158
108. Warshakoon NC, Wu S, Boyer A, et al. Design and synthesis of a series of novel pyrazolopyridines as HIF 1-alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett 2006;16:5687-5690
109. Stubbs CJ, Loenarz C, Mecinovic J, et al. Application of a proteolysis/mass spectrometry method for investigating the effects of inhibitors on hydroxylase structure. J Med Chem 2009;52:2799-2805
110. FibroGen, Inc. Novel thienopyridine compounds, and methods of use thereof. WO2006094292; 2006
111. FibroGen, Inc. Cyanoisoquinoline compounds and methods of use thereof. WO2007090068; 2007
112. FibroGen, Inc. Preparation of pyrrolopyridines and thiazolopyridines, particularly N-[(4-hydroxy-1H-pyrrolo [2,3-c]pyridin-5-yl)carbonyl]glycine and N-[(7-hydroxythiazolo[4,5-c]pyridine-6-yl)carbonyl]glycine derivatives, as hypoxia inducible factor hydroxylase modulators. WO2007115315; 2007
113. FibroGen, Inc. Isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions. WO2009073669; 2009
114. FibroGen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity. WO2009089547; 2009
115. FibroGen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors. WO2009100250; 2009
116. FibroGen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors. WO2010056767; 2010
117. FibroGen, Inc. Pyrrolo[1,2-b]pyridazine derivatives and their use as HIF modulators. WO2010022240; 2010
118. GlaxoSmithKline. Anti-infectives. WO2004052313; 2004
119. GlaxoSmithKline. Prolyl hydroxylase antagonists. WO2007038571; 2007
120. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2007103905; 2007
121. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2007136990; 2007
122. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009039323; 2009
123. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009039321; 2009
124. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009039322; 2009
125. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010022307; 2010
126. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009070644; 2009
127. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009073497; 2009
128. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009134850; 2009
129. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009134847; 2009
130. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2007150011; 2007
131. GlaxoSmithKline. N-Substituted glycine derivatives: prolyl hydroxylase inhibitors. US20080171756; 2008
132. GlaxoSmithKline. N-Substituted glycine derivatives: hydroxylase inhibitors. WO2008089052; 2008
133. GlaxoSmithKline. N-Glycinyl pyridinedicarboxamide derivatives as HIF prolyl hydroxylase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of anemia. WO2009158315; 2009
134. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010025087; 2010
135. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009049112; 2009
136. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009086044; 2009
137. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010022308; 2010
138. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010059549; 2010
139. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010059552; 2010
140. GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010059555; 2010
141. Amgen. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof. WO2007070359; 2007
142. Amgen. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof. WO2008076425; 2008
143. Stubbs CJ, Loenarz C, Mecinovic J, et al. Application of a proteolysis/mass spectrometry method for investigating the effects of inhibitors on hydroxylase structure. J Med Chem 2009;52:2799-2805
144. Amgen. Diazaquinolones that inhibit prolyl hydroxylase activity. WO2008137084; 2008
145. Amgen. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof. WO2008076427; 2008
146. Amgen. Indanone derivatives that inhibit prolyl hydroxylase. WO2008130508; 2008
147. Amgen. Quinolones and azaquinolones that inhibit prolyl hydroxylase. WO2008130600; 2008
148. Amgen. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity. WO2008137060; 2008
149. Bayer. 4-(Pyridin-3-yl)-2-(pyridine-2-yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-prolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases. WO2006114213; 2006
150. Bayer. Substituted dipyridyl-dihydropyrazolones and use thereof. WO2008067874; 2008
151. Bayer. Substituted heterocyclic compounds and their use. DE102007044032; 2007
152. Bayer. Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors. WO2008049538; 2008
153. Bayer. Substituted dihydropyrazolthiones and their use. DE102007048447; 2007
154. Bayer. Substituted dihydrotriazolones and their use. DE102007049157; 2007
155. Bayer. Substituted dihydropyrazolones for treating cardiovascular and haematological diseases. WO2008067871; 2008
156. Bayer. Substituted dihydropyrazolones and their use. US20090269420; 2009
157. Merck. Novel 1,8-naphthyridine compounds. WO2008130527; 2008
158. Merck. Tetrahydrofuropyridines. WO2009108496; 2009
159. Merck. Tetrahydrothienopyridines. WO2009108497; 2009
160. Merck. Tetrahydro-1H-pyrrolo fused pyridones. WO2009108499; 2009
161. Merck. Spiroindalones. WO2008144266; 2008
162. Merck. Spiroazaindoles. WO2009137291; 2009
163. Merck. Substituted 4-hydroxypyrimidine-5-carboxamides. WO2009117269; 2009
164. Janssen. Benzoimidazoles as prolyl hydroxylase inhibitors. WO2009134750; 2009
165. Benzoimidazoles glycinamides as prolyl hydroxylase inhibitors. WO2009134754; 2009
166. Procter & Gamble. Three dimensional coordinates of hypoxia inducible factor 1 alpha (HIF-1alpha)-prolyl hydroxylase (EGLN1) and uses thereof. US20080124740; 2008
167. Warshakoon NC, Wu S, Boyer A, et al. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydrolase inhibitors. Bioorg Med Chem Lett 2006;16:5517-5522
168. Warshakoon NC, Wu S, Boyer A, et al. Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydrolase inhibitors. Bioorg Med Chem Lett 2006;16:5616-5620
169. Warshakoon NC, Wu S, Boyer A, et al. A novel series of imidazo[1,2-a] pyridine derivatives as HIF-1alpha prolyl hydrolase inhibitors. Bioorg Med Chem Lett 2006;16:5598-5601
170. Procter & Gamble. Prolyl hydroxylase inhibitors and methods of use. US20070299086; 2007
171. CrystalGenomics. Pyridine derivatives and methods of use thereof. WO2009037570; 2009
172. CrystalGenomics. Phenol derivatives and methods of use thereof. WO2010018458; 2010
173. Kowa. Prophylactic and/or therapeutic agent for anemia comprising 2-phenylquinoline-4-carboxylic acid derivative as active ingredient. WO2009016812; 2009
174. Nagel S, Talbot NP, Mecinovic J, et al. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 2010;12:481-501
175. Urquilla P, Fong A, Oksanen S, et al. Upregulation of endogenous erythropoietin (EPO) in healthy subjects by inhibition of hypoxia inducible factor (HIF) prolyl hydroxylase. American Society of Hematology 2004 Annual Meeting. Blood 2004;104:abstract 174
176. Kim Y, Lin Q, Glazer PM, et al. Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 2009;9:425-434
177. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009;107:1053-1062
178. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732
179. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7
180. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684
181. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260
182. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972
183. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004
184. Ivan M, Kaelin WG. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001;11:27-34
185. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paragandlioma. N Engl J Med 2008;259:2685-2692
186. Amsel J, Waterbor JW, Oler J, et al. Relationship of site-specific cancer mortality rates to altitude. Carcinogenesis 1982;3:461-465
187. Weinberg CR, Brown KG, Hoel DG. Altitude, radiation, and mortality from cancer and heart disease. Radiat Res 1987;112:381-390
188. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-2514
189. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 2001;15:2520-2532
190. Mazzone M, Dettori D, de Oliveira RL, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:839-851
191. Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003;73:412-419 (Pubitemid 36921004)
192. Ang SO, Chen H, Kirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32:614-621
193. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004;103:3924-3932
194. Ribatti D. Erythropietin and tumor angiogenesis. Stem Cells Dev 2010;19:1-4
195. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006;103:654-659
196. Percy MJ, Furlow PW, Beer PA, et al. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 2007;110:2193-2196
197. Al-Sheikh M, Moradkhani K, Lopez M, et al. Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Blood Cells Mol Dis 2008;40:160-165
198. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia inducible factor 1 DNA binding activity: implications for models of hypoxia signal transduction. Blood 1993;82:3610-3615
199. Novartis Pharmaceuticals Corporation. Available from: . novartis.com/product/pi/pdf/exjade.pdf [Accessed 12 April 2010]
200. Lopez-Lazaro M. Role of oxygen in cancer: looking beyond hypoxia. Anticancer Agents Med Chem 2009;9:517-525
201. Spivak J. Daily aspirin -only half the answer. N Engl J Med 2004;350:99-101
202. Sergeyeva A, Gordeuk VR, Tokarev YN, et al. Congenital polycythemia in Chuvashia. Blood 1997;89:2148-2154
203. Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis-stimulating agents -time for a reevaluation. N Engl J Med 2010;362:189
204. Lee FS. Genetic causes of erythrocytosis and the oxygen-sensing pathway. Blood Rev 2008;22:321-332
205. Urquilla P. Up-regulation of endogenous EPO in healthy subjects by inhibition of HIF-PH. J Am Soc Nephrol 2004;15:546A
206. Gunzler V, Muthukrishnan E, Neumayer HH, et al. FG-2216 increases hemoglobin concentration in anemic patients with chronic kidney disease. J Am Soc Nephrol 2005;16:758A
207. Yildiz P. Molecular mechanisms of pulmonary hypertension. Clin Chim Acta 2009;403:9-16
208. Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;345:107-114
209. Maggiorini M, Leon-Velarde F. High-altitude pulmonary hypertension: a pathophysiological entity to different diseases. Eur Respir J 2003;22:1019-1025
210. Bushuev VI, Miasnikova GY, Sergueeva AI, et al. Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica 2006;91:744-749
211. Smith TG, Brooks JT, Balanos GM, et al. Mutation of von Hippel-Lindau tumor suppressor and human cardiopulmonary physiology. PLoS Med 2006;3:1178-1186
212. Allegra A, Giacobbe MS, Corvaia E, et al. Possible role of erythropoietin in the pathogenesis of chronic corpulmonale. Nephrol Dial Transplant 2005;20:2866-2867
213. Beumi M, Senatore M, Gallo GC, et al. Pulmonary hypertension and erythropoietin. Kidney Blood Press Res 2007;30:248-252
214. Ali O, Wharton J, Gibbs JSR, et al. Emerging therapies for pulmonary arterial hypertension. Expert Opin Investig Drugs 2007;16:803-818
215. Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol 2002;92:2501-2507
216. Smith TG, Balanos GM, Croft QP, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008;586:5999-6005
217. Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999;103:691-696
218. Brusselmans K, Compernolle V, Tjwa M, et al. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 2003;111:1519-1527
219. Hickey MM, Lam JC, Bezman NA, et al. Von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythrocytosis. J Clin Invest 2007;117:3879-3889
220. Hickey MM, Richardson T, Wang T, et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest 2010;120:827-839
221. Pappalardi MB, Martin JD, Jiang Y, et al. Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis. Biochemistry 2008;47:11165
222. Cummins EP, Berra E, Comeford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006;103:18154-18159
223. Wenger RH, Camenisch G, Stiehl DP, et al. HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting. Curr Pharm Des 2009;15:3886-3894
224. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008;4:152-156